IRD Stock Analysis: Buy, Sell, or Hold?
IRD - Opus Genetics, Inc. Common Stock
$3.90
-0.19 (-4.53%)
▼
5d:
-0.13%
30d:
-8.57%
90d:
-13.64%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When IRD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: IRD shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: IRD shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: IRD is currently trading at $3.90, which is considered oversold relative to its 30-day fair value range of $3.95 to $4.32.
Technical Outlook: Technically, IRD is in a strong uptrend. The price is currently testing key support at $3.88. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: IRD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.44 (+155.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IRD is in a strong uptrend. The price is currently testing key support at $3.88. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: IRD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.44 (+155.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.95 -
$4.32
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.5%)
- BULLISH: Trading 155.8% below Wall St target ($10.44)
Trading Range Analysis
30-Day Trading Range
$3.95 -
$4.32
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.88
Resistance Level
$4.68
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.76
Wall Street Target
$10.44
(+155.8%)
Revenue Growth (YoY)
-50.6%
Share & Embed Analysis
Last updated: June 24, 2026 1:22 PM ET
Data refreshes hourly during market hours. Next update: 2:22 PM
Data refreshes hourly during market hours. Next update: 2:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRD showing a specific setup today?
Insider Activity (6 Months)
2
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Ashwath Jayagopal
SELL
3719 shares
2026-03-16
George Magrath
SELL
24438 shares
2026-03-16
Joseph K Schachle
SELL
3719 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |